For US Healthcare Professionals only
PRESCRIBINGINFORMATION REQUEST
SAMPLES
NUZYRA is indicated for the treatment of Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in adults caused by select susceptible microorganisms.
WELCOME TO NUZYRA® CENTRAL
When you complete the prescription form below, information will be sent to NUZYRA Central, which will evaluate coverage and affordability options for your patient.
- Benefits Verification (BV)
- Prior Authorization Support
- Copay assistance
- Triage to network specialty pharmacy
- Evaluate for Patient Assistance Program
Please complete the fields below to prescribe NUZYRA for your patient.
WELCOME TO NUZYRA® CENTRAL
SUCCESS!
We have received your NUZYRA® (omadacycline) request. If the patient or HCP was not present at the time you submitted the request, they will receive a link (via email) to sign the consent and authorization. NUZYRA Central® understands the needs of your patient and based on their coverage, we will look for the most appropriate patient services available.
Questions? Call NUZYRA® Central Support Services at
Mon-Fri, 8 AM to 8 PM ET to speak with a representative.
ICD-10 Lookup
| ICD-10 | Description | |
|---|---|---|
There were no results matching your search terms. Please adjust and try again.
SAVE PROGRESS FOR LATER
SUCCESS!
Your resume code is {{ resumeCode }}.
You will need this code and your email address to continue filling out the form in the future.
RESUME PRIOR FORM SUBMISSION
SPECIALTY PHARMACY PARTNER FINDER
Please use the finder below to select a pharmacy that carries NUZYRA® (omadacycline) tablets.
* This information is current as of 04/19/2024.
NUZYRA is available at pharmacies in the NUZYRA Pharmacy Network. Paratek Pharmaceuticals, Inc. does not recommend or prefer the use of one pharmacy over another.
Inventory may vary. Check with your local pharmacy for availability and additional guidance.
Pharmacies near you
{{ loc.name }}
{{ loc.Address }}
{{ loc.city }}, {{ loc.state }} {{ loc.zipString }}
{{ loc.phone }}
Fax: {{ loc.fax }}
NUZYRA Pharmacy Network
All pharmacies are able to provide same day or next day delivery of NUZYRA.
{{ loc.name }}
{{ loc.Address }}
{{ loc.city }}, {{ loc.state }} {{ loc.zipString }}
{{ loc.phone }}
Fax: {{ loc.fax }}
NUZYRA® (omadacycline) is a tetracycline-class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms:
Community-Acquired Bacterial Pneumonia (CABP) caused by the following:
Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.
Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by the following:
Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Staphylococcus lugdunensis, Streptococcus pyogenes, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Enterococcus faecalis, Enterobacter cloacae, and Klebsiella pneumoniae.
USAGE
To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
NUZYRA is contraindicated in patients with known hypersensitivity to omadacycline or tetracycline-class antibacterial drugs, or to any of the excipients.
WARNINGS AND PRECAUTIONS
Mortality imbalance was observed in the CABP clinical trial with eight deaths (2%) occurring in patients treated with NUZYRA compared to four deaths (1%) in patients treated with moxifloxacin. The cause of the mortality imbalance has not been established. All deaths, in both treatment arms, occurred in patients > 65 years of age; most patients had multiple comorbidities. The causes of death varied and included worsening and/or complications of infection and underlying conditions. Closely monitor clinical response to therapy in CABP patients, particularly in those at higher risk for mortality.
The use of NUZYRA during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.
The use of NUZYRA during the second and third trimester of pregnancy, infancy and childhood up to the age of 8 years may cause reversible inhibition of bone growth.
Hypersensitivity reactions have been reported with NUZYRA. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with other tetracycline-class antibacterial drugs. NUZYRA is structurally similar to other tetracycline-class antibacterial drugs and is contraindicated in patients with known hypersensitivity to tetracycline-class antibacterial drugs. Discontinue NUZYRA if an allergic reaction occurs.
Clostridioides difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis. Evaluate if diarrhea occurs.
NUZYRA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions, including photosensitivity, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, hyperphosphatemia, pancreatitis, and abnormal liver function tests), have been reported for other tetracycline-class antibacterial drugs, and may occur with NUZYRA. Discontinue NUZYRA if any of these adverse reactions are suspected.
Prescribing NUZYRA in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2%) are nausea, vomiting, infusion site reactions, alanine aminotransferase increased, aspartate aminotransferase increased, gamma-glutamyl transferase increased, hypertension, headache, diarrhea, insomnia, and constipation.
DRUG INTERACTIONS
Patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage while taking NUZYRA.
Absorption of tetracyclines, including NUZYRA is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron containing preparations.
USE IN SPECIFIC POPULATIONS
Lactation: Breastfeeding is not recommended during treatment with NUZYRA.
Please see Full Prescribing Information for NUZYRA.